Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

PURPOSE: To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL). PATIENTS AND METHODS: Eligible patients had relapsed/refractory HCL after ≥ two prior therapies and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kreitman, Robert J., Tallman, Martin S., Robak, Tadeusz, Coutre, Steven, Wilson, Wyndham H., Stetler-Stevenson, Maryalice, FitzGerald, David J., Lechleider, Robert, Pastan, Ira
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2012
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3383181/
https://ncbi.nlm.nih.gov/pubmed/22355053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.1756
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller